Oral bisphosphonates improve Bone Mineral Density in adults with cystic fibrosis
In adults with Cystic Fibrosis (CF) we sought to establish the effect of oral bisphosphonate therapy. Bone densitometry measured by dual energy X-ray absorptiometry (DXA), and clinical patient data, were reviewed retrospectively. Eighty-one patients (median age 27 years) had baseline and follow-up D...
Gespeichert in:
| Veröffentlicht in: | Irish medical journal 2005-10, Vol.98 (9), p.270-273 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 273 |
|---|---|
| container_issue | 9 |
| container_start_page | 270 |
| container_title | Irish medical journal |
| container_volume | 98 |
| creator | Cawood, T J McKenna, M J Gallagher, C G Smith, D Wen, Y C Gibney, J Dodd, J D O'Shea, D |
| description | In adults with Cystic Fibrosis (CF) we sought to establish the effect of oral bisphosphonate therapy. Bone densitometry measured by dual energy X-ray absorptiometry (DXA), and clinical patient data, were reviewed retrospectively. Eighty-one patients (median age 27 years) had baseline and follow-up DXA, with an interval of 19.2 +/- 7.1 months. Thirty-six patients were treated with bisphosphonates (alendronate=23 and risedronate=13). Median follow-up Bone Mineral Density in the bisphosphonate group was 3.7% greater at the lumbar spine (95%CI 1.9 to 5.7%, P |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_68819088</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>68819088</sourcerecordid><originalsourceid>FETCH-LOGICAL-p124t-6826c80b2881e91e55f5e85d7e4582936e3e47336b97b15464c3d068a51e40b3</originalsourceid><addsrcrecordid>eNo1kMtOwzAURL0A0VL4BeQVu0i2b-w4SyiPIhWVRfeRndyoRnmR64Dy97SiLEazOToazQVbCgCVgBRqwa6JPoUABZm6YgtpQAgpzJJ97EbXcB9oOPSndC4i8dAOY_-N_LHvkL-HDk_QE3YU4sxDx101NZH4T4gHXs4UQ8nr4MeeAt2wy9o1hLfnXrH9y_N-vUm2u9e39cM2GaRKY2KsMqUVXlkrMZeoda3R6irDVFuVg0HANAMwPs-81KlJS6iEsU5LTIWHFbv_0x6Hfk1IsWgDldg0rsN-osIcvbmw9gjencHJt1gVwxhaN87F_wXwCz88Vlw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>68819088</pqid></control><display><type>article</type><title>Oral bisphosphonates improve Bone Mineral Density in adults with cystic fibrosis</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Cawood, T J ; McKenna, M J ; Gallagher, C G ; Smith, D ; Wen, Y C ; Gibney, J ; Dodd, J D ; O'Shea, D</creator><creatorcontrib>Cawood, T J ; McKenna, M J ; Gallagher, C G ; Smith, D ; Wen, Y C ; Gibney, J ; Dodd, J D ; O'Shea, D</creatorcontrib><description>In adults with Cystic Fibrosis (CF) we sought to establish the effect of oral bisphosphonate therapy. Bone densitometry measured by dual energy X-ray absorptiometry (DXA), and clinical patient data, were reviewed retrospectively. Eighty-one patients (median age 27 years) had baseline and follow-up DXA, with an interval of 19.2 +/- 7.1 months. Thirty-six patients were treated with bisphosphonates (alendronate=23 and risedronate=13). Median follow-up Bone Mineral Density in the bisphosphonate group was 3.7% greater at the lumbar spine (95%CI 1.9 to 5.7%, P<0.0005) and 2.4% greater at the femur (95%CI 0.8 to 3.9%, P<0.005) than the group not treated with bisphosphonates. Oral bisphosphonate therapy had a beneficial effect on BMD in adults with CF.</description><identifier>ISSN: 0332-3102</identifier><identifier>PMID: 16300106</identifier><language>eng</language><publisher>Ireland</publisher><subject>Administration, Oral ; Adult ; Bone Density - physiology ; Bone Density Conservation Agents - therapeutic use ; Case-Control Studies ; Cystic Fibrosis - physiopathology ; Diphosphonates - therapeutic use ; Female ; Humans ; Male ; Osteoporosis - drug therapy ; Osteoporosis - physiopathology ; Retrospective Studies</subject><ispartof>Irish medical journal, 2005-10, Vol.98 (9), p.270-273</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16300106$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cawood, T J</creatorcontrib><creatorcontrib>McKenna, M J</creatorcontrib><creatorcontrib>Gallagher, C G</creatorcontrib><creatorcontrib>Smith, D</creatorcontrib><creatorcontrib>Wen, Y C</creatorcontrib><creatorcontrib>Gibney, J</creatorcontrib><creatorcontrib>Dodd, J D</creatorcontrib><creatorcontrib>O'Shea, D</creatorcontrib><title>Oral bisphosphonates improve Bone Mineral Density in adults with cystic fibrosis</title><title>Irish medical journal</title><addtitle>Ir Med J</addtitle><description>In adults with Cystic Fibrosis (CF) we sought to establish the effect of oral bisphosphonate therapy. Bone densitometry measured by dual energy X-ray absorptiometry (DXA), and clinical patient data, were reviewed retrospectively. Eighty-one patients (median age 27 years) had baseline and follow-up DXA, with an interval of 19.2 +/- 7.1 months. Thirty-six patients were treated with bisphosphonates (alendronate=23 and risedronate=13). Median follow-up Bone Mineral Density in the bisphosphonate group was 3.7% greater at the lumbar spine (95%CI 1.9 to 5.7%, P<0.0005) and 2.4% greater at the femur (95%CI 0.8 to 3.9%, P<0.005) than the group not treated with bisphosphonates. Oral bisphosphonate therapy had a beneficial effect on BMD in adults with CF.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Bone Density - physiology</subject><subject>Bone Density Conservation Agents - therapeutic use</subject><subject>Case-Control Studies</subject><subject>Cystic Fibrosis - physiopathology</subject><subject>Diphosphonates - therapeutic use</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Osteoporosis - drug therapy</subject><subject>Osteoporosis - physiopathology</subject><subject>Retrospective Studies</subject><issn>0332-3102</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kMtOwzAURL0A0VL4BeQVu0i2b-w4SyiPIhWVRfeRndyoRnmR64Dy97SiLEazOToazQVbCgCVgBRqwa6JPoUABZm6YgtpQAgpzJJ97EbXcB9oOPSndC4i8dAOY_-N_LHvkL-HDk_QE3YU4sxDx101NZH4T4gHXs4UQ8nr4MeeAt2wy9o1hLfnXrH9y_N-vUm2u9e39cM2GaRKY2KsMqUVXlkrMZeoda3R6irDVFuVg0HANAMwPs-81KlJS6iEsU5LTIWHFbv_0x6Hfk1IsWgDldg0rsN-osIcvbmw9gjencHJt1gVwxhaN87F_wXwCz88Vlw</recordid><startdate>200510</startdate><enddate>200510</enddate><creator>Cawood, T J</creator><creator>McKenna, M J</creator><creator>Gallagher, C G</creator><creator>Smith, D</creator><creator>Wen, Y C</creator><creator>Gibney, J</creator><creator>Dodd, J D</creator><creator>O'Shea, D</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>200510</creationdate><title>Oral bisphosphonates improve Bone Mineral Density in adults with cystic fibrosis</title><author>Cawood, T J ; McKenna, M J ; Gallagher, C G ; Smith, D ; Wen, Y C ; Gibney, J ; Dodd, J D ; O'Shea, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p124t-6826c80b2881e91e55f5e85d7e4582936e3e47336b97b15464c3d068a51e40b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Bone Density - physiology</topic><topic>Bone Density Conservation Agents - therapeutic use</topic><topic>Case-Control Studies</topic><topic>Cystic Fibrosis - physiopathology</topic><topic>Diphosphonates - therapeutic use</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Osteoporosis - drug therapy</topic><topic>Osteoporosis - physiopathology</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cawood, T J</creatorcontrib><creatorcontrib>McKenna, M J</creatorcontrib><creatorcontrib>Gallagher, C G</creatorcontrib><creatorcontrib>Smith, D</creatorcontrib><creatorcontrib>Wen, Y C</creatorcontrib><creatorcontrib>Gibney, J</creatorcontrib><creatorcontrib>Dodd, J D</creatorcontrib><creatorcontrib>O'Shea, D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Irish medical journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cawood, T J</au><au>McKenna, M J</au><au>Gallagher, C G</au><au>Smith, D</au><au>Wen, Y C</au><au>Gibney, J</au><au>Dodd, J D</au><au>O'Shea, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oral bisphosphonates improve Bone Mineral Density in adults with cystic fibrosis</atitle><jtitle>Irish medical journal</jtitle><addtitle>Ir Med J</addtitle><date>2005-10</date><risdate>2005</risdate><volume>98</volume><issue>9</issue><spage>270</spage><epage>273</epage><pages>270-273</pages><issn>0332-3102</issn><abstract>In adults with Cystic Fibrosis (CF) we sought to establish the effect of oral bisphosphonate therapy. Bone densitometry measured by dual energy X-ray absorptiometry (DXA), and clinical patient data, were reviewed retrospectively. Eighty-one patients (median age 27 years) had baseline and follow-up DXA, with an interval of 19.2 +/- 7.1 months. Thirty-six patients were treated with bisphosphonates (alendronate=23 and risedronate=13). Median follow-up Bone Mineral Density in the bisphosphonate group was 3.7% greater at the lumbar spine (95%CI 1.9 to 5.7%, P<0.0005) and 2.4% greater at the femur (95%CI 0.8 to 3.9%, P<0.005) than the group not treated with bisphosphonates. Oral bisphosphonate therapy had a beneficial effect on BMD in adults with CF.</abstract><cop>Ireland</cop><pmid>16300106</pmid><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0332-3102 |
| ispartof | Irish medical journal, 2005-10, Vol.98 (9), p.270-273 |
| issn | 0332-3102 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68819088 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Administration, Oral Adult Bone Density - physiology Bone Density Conservation Agents - therapeutic use Case-Control Studies Cystic Fibrosis - physiopathology Diphosphonates - therapeutic use Female Humans Male Osteoporosis - drug therapy Osteoporosis - physiopathology Retrospective Studies |
| title | Oral bisphosphonates improve Bone Mineral Density in adults with cystic fibrosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T08%3A28%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oral%20bisphosphonates%20improve%20Bone%20Mineral%20Density%20in%20adults%20with%20cystic%20fibrosis&rft.jtitle=Irish%20medical%20journal&rft.au=Cawood,%20T%20J&rft.date=2005-10&rft.volume=98&rft.issue=9&rft.spage=270&rft.epage=273&rft.pages=270-273&rft.issn=0332-3102&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E68819088%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=68819088&rft_id=info:pmid/16300106&rfr_iscdi=true |